2. Search Result
Search Result
Results for "

cancer immunotherapy

" in MedChemExpress (MCE) Product Catalog:

79

Inhibitors & Agonists

4

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

15

Peptides

10

Inhibitory Antibodies

8

Natural
Products

4

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-163041
    PD-1/PD-L1-IN-36

    		PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/PD-L1-IN-36 (Compound 2k) is a PD-1/PD-L1 complex inhibitor (IC50: 15 nM). PD-1/PD-L1-IN-36 can be used for research of cancer immunotherapy .
    PD-1/PD-L1-IN-36
  • HY-P10217
    PD-1/PD-L1-IN-42

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC50 of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy .
    PD-1/PD-L1-IN-42
  • HY-P10862A
    AH-D peptide TFA

    		Virus Protease Infection Cancer
    AH-D peptide TFA is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy .
    AH-D peptide TFA
  • HY-170899
    TLR7 agonist 28

    		Toll-like Receptor (TLR) Cancer
    TLR7 agonist 28 (compound 3) is a potent TLR7 agonist. TLR7 agonist 28 can conjugat to antitumor monoclonal antibodies (mAbs) for cancer immunotherapy .
    TLR7 agonist 28
  • HY-P991126
    Ciltistotug

    		TNF Receptor Inflammation/Immunology Cancer
    Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy .
    Ciltistotug
  • HY-P10862
    AH-D peptide

    		Virus Protease Infection Cancer
    AH-D peptide is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy .
    AH-D peptide
  • HY-164072
    DBCO-Dextran

    		Biochemical Assay Reagents Others Cancer
    DBCO-Dextran is a dibenzocyclooctyne-modified dextran with excellent click chemistry activity and biocompatibility, which can be used in cancer immunotherapy and bioimaging research .
    DBCO-Dextran
  • HY-149520
    HPK1-IN-39

    		MAP4K Cancer
    HPK1-IN-39 (Compound 10n) is a selective HPK1 Inhibitor (IC50: 29 nM). HPK1-IN-39 inhibits the phosphorylation of SLP76. HPK1-IN-39 can be used for research of cancer immunotherapy .
    HPK1-IN-39
  • HY-P991718
    Tagmokitug

    		CCR Inflammation/Immunology Cancer
    Tagmokitug is a humanized IgG1κ monoclonal antibody inhibitor targeting CCR8. Tagmokitug has antitumor activity. Tagmokitug can be used for tumor immunotherapy research, such as breast, colon and lung cancer .
    Tagmokitug
  • HY-155675
    TPPC

    		Others Cancer
    TPPC, a porphyrin cholesterol conjugate, can render cancer cells more sensitive to ICIs. TPPC can enhance photodynamic immunotherapy toward lung cancer .
    TPPC
  • HY-P991719
    Tambotatug

    YL201 antibody

    		 CD276/B7-H3 Inflammation/Immunology Cancer
    Tambotatug is a humanized IgG1κ monoclonal antibody inhibitor targeting CD276/B7-H3. Tambotatug has antitumor activity. Tambotatug can be used for tumor immunotherapy like colorectal cancer (CRC) research .
    Tambotatug
  • HY-133123
    EP4 receptor antagonist 1

    		Prostaglandin Receptor Inflammation/Immunology Cancer
    EP4 receptor antagonist 1 is a highly potent and selective competitive prostanoid EP4 receptor antagonist for cancer immunotherapy. EP4 receptor antagonist 1 inhibits human and mouse EP4 receptor with IC50s of 6.1 nM and 16.2 nM, respectively. IC50s >10 μM for human EP1, EP2,and EP3 receptors .
    EP4 receptor antagonist 1
  • HY-P99175
    KWAR 23

    		CD47 Cancer
    KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research .
    KWAR 23
  • HY-153544
    TLR7/8 agonist 9

    		Toll-like Receptor (TLR) Cancer
    TLR7/8 agonist 9 (Compound 25a) is a TLR7/8 agonist, with EC50s of 40 nM and 23 nM for hTLR7/8. TLR7/8 agonist 9 has anti-tumor activity and improves the antitumor activity of PD-1/PD-L1 blockade. TLR7/8 agonist 9 can be used for research of cancer immunotherapy .
    TLR7/8 agonist 9
  • HY-33299
    Serpin B9-IN-1

    BTCA

    		 Biochemical Assay Reagents Cancer
    Serpin B9-IN-1 (BTCA) is an inhibitor that specifically targets Serpin B9 (SB9); SB9 is a natural inhibitor of granzyme B (GrB) , but may promote the metastasis of lung cancer cells into the bone marrow. SB9-overexpressing cancer cells promote proliferation and metastasis in an immune cell-dependent manner by binding to GrB. Inhibition of SB9 by Serpin B9-IN-1 significantly inhibits immunotherapy of lung cancer bone metastases in the caudal artery (CA) mouse model (LCBM) .
    Serpin B9-IN-1
  • HY-146231A
    SS47 TFA

    		MAP4K PROTACs Inflammation/Immunology Cancer
    SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies . SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    SS47 TFA
  • HY-178097
    HPK1-IN-62

    		MAP4K Cancer
    HPK1-IN-62 is a selective and orally active HPK-1 inhibitor with an IC50 of 1.22 nM. HPK1-IN-62 significantly improves GLK selectivity (> 665-fold) and LCK selectivity (> 1095-fold). HPK1-IN-62 enhances T-cell activation and demonstrated synergistic effects when combined with anti-mPD-1 therapy in the MC38 tumor model, inhibiting a tumor growth. HPK1-IN-62 can be used in the researchs of colon cancer and cancer immunotherapy .
    HPK1-IN-62
  • HY-P11058
    OVA(250-264)

    OVAp

    		 MHC Cancer
    OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8 + T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research .
    OVA(250-264)
  • HY-P1813
    PSA1 (141-150)

    PSA-Peptide

    		 Prostaglandin Receptor Cancer
    PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments .
    PSA1 (141-150)
  • HY-177483
    OART

    Oxaliplatin-artesunate

    		 Ferroptosis Mitochondrial Metabolism Glutathione Peroxidase Transferrin Receptor MMP Dihydroorotate Dehydrogenase Cancer
    OART (Oxaliplatin-artesunate) is a ferroptosis inducer. OART significantly inhibits tumor cell proliferation. OART induces cytoplasmic and mitochondrial LPO to promote tumor ferroptosis, via destroying glutathione-mediated ferroptosis defense system and enhancing iron-dependent Fenton reaction. OART enhances tumor immunogenicity, transforming tumor environment from immunosuppressive to immunosensitive. OART has strong tumor regression in tumor-bearing mouse models. OART can be used for cancer immunotherapy research .
    OART
  • HY-P991634
    IBI-325

    		CD73 TNF Receptor Interleukin Related IFNAR Inflammation/Immunology Cancer
    IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research .
    IBI-325
  • HY-P9902
    Pembrolizumab
    Maximum Cited Publications
    24 Publications Verification

    MK-3475; Lambrolizumab

    		 PD-1/PD-L1 Cancer
    Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
    Pembrolizumab
  • HY-N10116A
    Calamenene

    		Others Cancer
    Calamenene is a major sesquiterpenoid, which could be isolated from Cupressus bakeri foliage. Calamenene affects the maturation and function of human monocyte-derived dendritic cells .
    Calamenene
  • HY-20457
    TL8-506

    		Toll-like Receptor (TLR) Bacterial Interleukin Related Inflammation/Immunology Cancer
    TL8-506 is a specific TLR8 agonist with an EC50 of 30 nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy .
    TL8-506
  • HY-144072
    MRS4620

    		CD73 Inflammation/Immunology Cancer
    MRS4620 is a potent CD73 inhibitor, with a Ki of 0.436 nM. MRS4620 can be use for the research of cancer immunoresearch .
    MRS4620
  • HY-172596
    TYK2 activator-1

    		JAK Inflammation/Immunology
    TYK2 activator-1 (16b) is a TYK2 activator with anEC50 of 1.78 μM. TYK2 activator-1 inhibits JAK2 and JAK3 with the IC50 values of 6.8 and 6.3 μM, respectively .
    TYK2 activator-1
  • HY-177568
    Mozistobart zoratolimod

    TAC-001

    		 CD22 Toll-like Receptor (TLR) Antibody-Oligonucleotide Conjugates (AOCs) Cancer
    Mozistobart zoratolimod is an antibody-oligonucleotide conjugate (AOC) composed of a humanized monoclonal antibody (HY-P990930 Mozistobart) targe ting CD22 linked to a TLR9 agonist. It is used for the study of cancer immunotherapy.
    Mozistobart zoratolimod
  • HY-P991125
    Cenzestotug

    YH-002

    		 TNF Receptor Inflammation/Immunology Cancer
    Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy .
    Cenzestotug
  • HY-169936
    ERAP1-IN-3

    		Aminopeptidase Inflammation/Immunology Cancer
    ERAP1-IN-3 (compound 13) is a potent endoplasmic reticulum aminopeptidase 1 (ERAP1) inhibitor, with a pIC50 of 8.6. ERAP1-IN-3 has potential for the research of cancer immunotherapy and autoimmune disease .
    ERAP1-IN-3
  • HY-P10837
    LAG-3 cyclic peptide inhibitor 12

    		LAG-3 Inflammation/Immunology Cancer
    LAG-3 cyclic peptide inhibitor 12 (Cyclic peptide 12) is an inhibitor of LAG-3 with an IC50 value of 4.45 μM and a Ki value of 2.66 µM .
    LAG-3 cyclic peptide inhibitor 12
  • HY-N1420AR
    Rhamnose monohydrate (Standard)

    L-Rhamnose monohydrate (Standard)

    		 Reference Standards Endogenous Metabolite MMP Interleukin Related PKA Infection Metabolic Disease Cancer
    Rhamnose monohydrate (Standard) is the analytical standard of Rhamnose monohydrate (HY-N1420A). Rhamnose monohydrate (L-Rhamnose monohydrate) is an orally active deoxysugar. Rhamnose monohydrate can inhibit levels of pro-inflammatory interleukin and matrix metalloproteinases (MMPs) in skin aging models. Rhamnose can promote the phosphorylation levels of PKA substrates and HSL in SVF-derived adipocytes, stimulating PKA signaling. Rhamnose monohydrate can act against obesity in mice by stimulating fat dopamine receptors and inducing thermogenesis. Rhamnose monohydrate shows anti-aging effects. Rhamnose monohydrate can be used in the study of Ehrlich’s solid tumors and sarcomas .
    Rhamnose monohydrate (Standard)
  • HY-130607
    IDO1-IN-2

    		Indoleamine 2,3-Dioxygenase (IDO) Inflammation/Immunology Cancer
    IDO1-IN-2 (compound 16) is a potent and selective IDO1 inhibitor with IC50s of 81 nM, 59 nM (mouse) and 28 nM (rat), respectively. IDO1-IN-2 has anti-cancer activity .
    IDO1-IN-2
  • HY-108681
    680C91
    2 Publications Verification

    		 Collagen Neurological Disease Inflammation/Immunology Cancer
    680C91 is an orally active, selective tryptophan 2,3-dioxygenase (TDO) inhibitor with a Ki of 51 nM. TDO is the key enzyme of tryptophan catabolism. 680C91 can be used for the research of cancer immunotherapy and Alzheimer’s Disease .
    680C91
  • HY-P991142
    Isuventatug

    		MHC Inflammation/Immunology Cancer
    Isuventatug is a monoclonal antibody targeting human MICA (MHC class I chain-related molecule A) and MICB (MHC class I chain-related molecule B). Isuventatug binds to MICA and MICB to regulate the interaction between immune cells and tumor cells, exerting antitumor activity. Isuventatug is promising for research of cancer immunotherapy .
    Isuventatug
  • HY-162726
    GCS-11

    		Interleukin Related Cancer
    GCS-11 is a powerful natural killer T (NKT) cell agonist. It boosts the production of IFN-γ and IL-4, with a particular selectivity for IFN-γ. GCS-11 exhibits anticancer activity. GCS-11 has the potential for research into cancer immunotherapies or vaccine development as a promising adjuvant .
    GCS-11
  • HY-13735H
    Quinacrine acetate

    Acriquine acetate

    		 Parasite Sodium Channel DNA Stain Apoptosis Cancer
    Quinacrine (Acriquine) acetate is a small molecule modulator of the cGAS-STING-TBK1 signaling pathway, possessing immune stimulatory activity. Quinacrine acetate has been explored for its potential therapeutic applications in enhancing anti-tumor immunity. Quinacrine acetate can improve the effectiveness of cancer immunotherapies by addressing the poor immunogenicity of various tumors. Quinacrine acetate also presents a promising strategy for overcoming the limitations associated with immune checkpoint inhibitors in cancer treatment.
    Quinacrine acetate
  • HY-126321
    RORγt agonist 1

    		ROR Cancer
    RORγt agonist 1 (compound 14) is a potent, orally bioavailable RORγt agonist with an EC50 of 20.8 nM. RORγt agonist 1 showes high metabolic stability, improved aqueous solubility and excellent mouse PK profile. RORγt agonist 1 is a potential candidate of RORγt agonist for cancer immunotherapy .
    RORγt agonist 1
  • HY-155109
    Antitumor agent-114

    		STING Inflammation/Immunology Cancer
    Antitumor agent-114 is a potent stimulator of interferon genes (STING) agonist. Antitumor agent-114 activates immunity and reduces tumor volume in a mouse model of breast cancer. Antitumor agent-114 can be used for immunity and cancer diseases research .
    Antitumor agent-114
  • HY-111786
    LHC-165

    		Toll-like Receptor (TLR) Cancer
    LHC-165 is a TLR7 agonist. LHC-165 has potential to used in study of solid tumors .
    LHC-165
  • HY-20457G
    TL8-506

    		Toll-like Receptor (TLR) Bacterial Interleukin Related Inflammation/Immunology Cancer
    TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30 nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy .
    TL8-506
  • HY-116604
    RLX

    PD 139530

    		 PI3K Akt Cancer
    RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness .
    RLX
  • HY-143324
    A2AAR/HDAC-IN-1

    		HDAC Adenosine Receptor Cancer
    A2AAR/HDAC-IN-1 (compound 14c) is an orally active, potent and balanced A2AAR/HDAC dual inhibitor, with a Ki of 163.5 nM for A2AAR and an IC50 of 145.3 nM for HDAC1. A2AAR/HDAC-IN-1 shows anticancer activity .
    A2AAR/HDAC-IN-1
  • HY-116604A
    RLX hydrochloride

    PD 139530 hydrochloride

    		 PI3K Akt Cancer
    RLX (PD 139530) hydrochloride is the hydrochloride of RLX (HY-116604). RLX is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness .
    RLX hydrochloride
  • HY-163719
    PARP7-IN-22

    		PARP Cancer
    PARP7-IN-22 (XLY-1) is a PARP7 inhibitor with an IC50 of 0.6 nM. PARP7-IN-22 (XLY-1) is orally active, enhances type I interferon signaling in vitro, restores type I interferon signaling, promotes T cell infiltration into tumor tissues, and significantly inhibits tumor growth. PARP7-IN-22 shows promise for research in the field of cancer immunotherapy .
    PARP7-IN-22
  • HY-112880
    c-(2'FdAMP-2'FdIMP)

    		Drug Derivative STING NF-κB IFNAR Interleukin Related Infection Cancer
    c-(2'FdAMP-2'FdIMP) (Compound 52),a derivative of cAIMP (HY-134375), is a cyclic dinucleotide (CDN). c-(2'FdAMP-2'FdIMP) is a STING activator and significantly induce STING-dependent IRF and NF-κB pathway signaling. c-(2'FdAMP-2'FdIMP) can be used for STING-based immunotherapy, such as cancers and infectious diseases research .
    c-(2'FdAMP-2'FdIMP)
  • HY-P10417
    RTDLDSLRTYTL

    		Integrin Others Cancer
    RTDLDSLRTYTL is an Alpha (v) beta (6) integrin (avb6) inhibitor with high affinity and specificity. RTDLDSLRTYTL binds to avb6 integrin, a peptide sequence that activates cytotoxicity and cytokine production in T cells, such as interferon-gamma. RTDLDSLRTYTL is designed through a chimeric T cell antigen receptor (CAR) so that T cells can be redirected to specifically recognize and attack tumor cells. RTDLDSLRTYTL can be used in the research of cancer immunotherapy and targeted drug development .
    RTDLDSLRTYTL
  • HY-161518
    PD-1/PD-L1-IN-44

    		PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-44 (Compound 22) selectively inhibits PD-1/PD-L1 proteins (IC50=1.21 nM). PD-1/PD-L1-IN-44 inhibits tumor growth without toxicity in animal models and increases CD8 + cell infiltration .
    PD-1/PD-L1-IN-44
  • HY-W1128213
    IKZF2-degrader 2

    		Molecular Glues IKZF Family Inflammation/Immunology Cancer
    IKZF2-degrader 2 is a selective and orally active IKZF2 molecular glue degrader with DC50 values of 0.5 nM and 1.8 nM in HiBit and FACS. The IKZF2-degrader 2 mediates the ubiquitination and degradation of target proteins by recruiting the CRL4-CRBN E3 ubiquitin ligase. IKZF2-degrader 2 displays moderate degradation against SALL4 with a DC50 of 9 nM but does not induce any significant degradation towards IKZF1, IKZF3, CK1α and GSPT1. IKZF2-degrader 2 can be used for the study of cancer immunology .
    IKZF2-degrader 2
  • HY-119109
    Laminaran
    1 Publications Verification

    		 Endogenous Metabolite Cancer
    Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities . Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds . Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy .
    Laminaran
  • HY-173462
    TBK1-IN-2

    		IKK Cancer
    TBK1-IN-2 (Compound A1) is a potent TBK1 inhibitor (IC50: 775 pM). TBK1-IN-2 binds to TBK1 through stable hydrogen bonds and π-π stacking, inhibiting IRF3 phosphorylation. TBK1-IN-2 synergizes with TNF/IFNγ to enhance immune-mediated tumor cell death. TBK1-IN-2 can be used in cancer immunotherapy research .
    TBK1-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: